Sort   by:  
 Page size 
UnknownAppropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society.
Not available
S-EPMC11670059 | biostudies-literature
UnknownA pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.
Not available
S-EPMC5863135 | biostudies-literature
UnknownCarboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Not available
S-EPMC6886237 | biostudies-literature
UnknownPembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
Not available
S-EPMC6886233 | biostudies-literature
UnknownChanges in older adults' life space during lung cancer treatment: A mixed methods cohort study.
Not available
S-EPMC8742783 | biostudies-literature
UnknownImmunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.
Not available
S-EPMC8815444 | biostudies-literature
UnknownGermline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
Not available
S-EPMC11213033 | biostudies-literature
UnknownSystematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Not available
S-EPMC6276906 | biostudies-literature
UnknownEvolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Not available
S-EPMC5709185 | biostudies-literature
UnknownLiver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Not available
S-EPMC5749922 | biostudies-literature
Sort   by:  
 Page size